Beta-adrenergic gene transfer and myocardial function: Heart failure (HF), a condition resulting from a variety of cardiac diseases, is a major cause of morbidity and mortality in this nation. It is well documented that a characteristic of chronic HF is the marked impairment of the beta-adrenergic receptor (beta-AR) system which contributes to the dysfunction of the heart. Adding to its importance, is the fact that drugs which act by altering beta-AR signal transduction are at the forefront of conventional HF therapeutic strategies. Alternative therapeutic strategies for improving myocardial performance are of significant interest and increasing beta-AR signaling properties represents a potential novel intervention to improve cardiac function. This proposal capitalizing on the recent discoveries that cardiac-overexpression of either beta-ARs or an inhibitor of beta-AR desensitization in transgenic mice causes marked improvement of in vivo cardiac contractility, is formulated to learn whether these transgenes will render a similar effect if delivered exogenously to adult myocardium. In addition, gene transfer of beta-AR transgenes will increase the understanding of the role of this critical signaling system in normal and compromised heart function. The Central Hypothesis is that efficient gene transfer to adult myocardium of DNA's encoding specific beta-AR-signaling components will alter cardiac function. To test this hypothesis, a model of gene transfer to the adult rabbit heart consisting of percutaneous coronary artery catherterization and adenovirus injection will be utilized. The associated Specific Aims are: (1) To optimize intra-coronary adenovirus delivery to the rabbit heart of transgenes consisting of various beta-AR signaling components and to study the biochemical consequences of altered adrenergic signaling. (2) T determine the in vivo physiologic effects of the delivered beta-AR transgenes and cardiac responses to beta-agonists in treated rabbit myocardium. (3) To test the validity of using beta-AR gene transfer to improve heart function during disease states by applying it to an experimental model of rabbit HF.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL056205-02
Application #
2857879
Study Section
Cardiovascular and Renal Study Section (CVB)
Project Start
1998-01-01
Project End
2000-12-31
Budget Start
1999-01-01
Budget End
1999-12-31
Support Year
2
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Duke University
Department
Surgery
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Zhang, Xue-Qian; Wang, JuFang; Song, Jianliang et al. (2015) Regulation of L-type calcium channel by phospholemman in cardiac myocytes. J Mol Cell Cardiol 84:104-11
Hoffman, Nicholas E; Miller, Barbara A; Wang, JuFang et al. (2015) Ca²? entry via Trpm2 is essential for cardiac myocyte bioenergetics maintenance. Am J Physiol Heart Circ Physiol 308:H637-50
Ritterhoff, Julia; Völkers, Mirko; Seitz, Andreas et al. (2015) S100A1 DNA-based Inotropic Therapy Protects Against Proarrhythmogenic Ryanodine Receptor 2 Dysfunction. Mol Ther 23:1320-1330
Weber, C; Neacsu, I; Krautz, B et al. (2014) Therapeutic safety of high myocardial expression levels of the molecular inotrope S100A1 in a preclinical heart failure model. Gene Ther 21:131-8
Miller, Barbara A; Hoffman, Nicholas E; Merali, Salim et al. (2014) TRPM2 channels protect against cardiac ischemia-reperfusion injury: role of mitochondria. J Biol Chem 289:7615-29
Bathgate-Siryk, Ashley; Dabul, Samalia; Pandya, Krunal et al. (2014) Negative impact of ?-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms. Hypertension 63:404-12
Wang, JuFang; Song, Jianliang; Gao, Erhe et al. (2014) Induced overexpression of phospholemman S68E mutant improves cardiac contractility and mortality after ischemia-reperfusion. Am J Physiol Heart Circ Physiol 306:H1066-77
Lymperopoulos, Anastasios; Rengo, Giuseppe; Koch, Walter J (2013) Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res 113:739-53
Raake, Philip W J; Schlegel, Philipp; Ksienzyk, Jan et al. (2013) AAV6.?ARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur Heart J 34:1437-47
Pleger, Sven T; Brinks, Henriette; Ritterhoff, Julia et al. (2013) Heart failure gene therapy: the path to clinical practice. Circ Res 113:792-809

Showing the most recent 10 out of 95 publications